More than just a trip – the longevity potential of psychedelics

Terran Biosciences founder on longevity-psychedelic crossovers, targeting neurodegeneration and making history.
Terran Biosciences, a CNS-focused biotech platform company, is developing transformative therapeutics and technologies for patients with neurological and psychiatric diseases. As well as targeting schizophrenia, Terran’s novel drug Idazoxan (which it has licensed from Pierre Fabre, and for which it holds the global development and commercialization rights) can be used to treat Alzheimer’s and also comes as an extended-release version that enables once-daily dosing. A treatment for Parkinson’s psychosis is also in the pipeline.

Longevity.Technology: Terran has had a busy year; with an exclusive licensing deal with French pharma Pierre Fabre, the first cohort dosed in human clinical trial of its novel lead compound Idazoxan and a suite of IP publications all in the bag, Terran certainly isn’t short of news for its festive round robin.

Terran has one of the largest psychedelic development programs in the industry, and is leveraging psychedelics with a long history of human use, including psilocybin, LSD and MDMA. It’s no wonder, then, that that Terran had a significant presence at Wonderland earlier this year, and during the event, we were lucky enough to sit down with Terran’s founder and CEO, Sam Clark, MD PhD.

More than just a trip – the longevity potential of psychedelics